Hyperammonemia in the ICU: Causes, Lactulose, Rifaximin, CRRT
Executive Summary
1. Pathophysiology & Cerebral Toxicity
Ammonia (NH3) is the byproduct of amino acid catabolism plus gut bacterial protein degradation. Under normal physiology the liver clears ammonia via the urea cycle (urea cycle enzymes: CPS1, OTC, ASS1, ASL, ARG1) into urea, which is excreted renally. When the liver cannot clear ammonia — due to hepatic failure, portosystemic shunting, urea cycle enzyme deficiency, or drug-induced inhibition — circulating ammonia rises into the toxic range.
The brain is the principal target of ammonia toxicity. Ammonia crosses the blood-brain barrier and enters astrocytes, where glutamate is conjugated with NH3 by glutamine synthetase to form glutamine. Accumulating glutamine is osmotically active, drawing water into astrocytes, producing astrocyte swelling and ultimately cerebral edema. Mitochondrial dysfunction, oxidative stress, and disrupted neurotransmitter balance compound the injury. Ammonia levels above 200 µmol/L correlate strongly with cerebral edema risk; levels above 300 µmol/L are associated with brain herniation.
Other contributors to encephalopathy in the hyperammonemic patient include hyponatremia, hypoglycemia, sedative effects, sepsis, and uremia in mixed metabolic encephalopathy. Identifying the dominant driver guides therapy.
2. Etiologies: HE, UCD, Valproate, Other
Hepatic encephalopathy (HE) from cirrhosis or acute liver failure is the most common cause in adult ICU patients. Triggers in cirrhotic patients include GI bleeding, infection (especially SBP), constipation, electrolyte abnormalities (hypokalemia drives renal NH3 production), excess dietary protein, sedatives, and noncompliance with lactulose. The West Haven criteria grade HE severity from grade I (mild confusion) to grade IV (coma).
Drug-induced hyperammonemia in patients without underlying liver disease is the most commonly missed cause in adult ICUs. Valproate is the leading offender, producing hyperammonemia by carnitine depletion + urea cycle inhibition. Even therapeutic valproate levels can produce severe hyperammonemia, particularly in patients with subclinical urea cycle defects unmasked by valproate. Topiramate, carbamazepine, glycine-containing TPN, and chemotherapy (5-FU, asparaginase) are other recognized causes.
Urea cycle defects (UCDs) — most commonly ornithine transcarbamylase (OTC) deficiency, X-linked — can present in adulthood unmasked by stress, GI bleed, post-bariatric surgery, or chronic TPN. Plasma amino acid analysis (low citrulline + arginine, high glutamine) and urinary orotic acid distinguish OTC deficiency from other UCDs. The diagnosis matters because nitrogen scavenger therapy (sodium benzoate + sodium phenylacetate IV) plus arginine supplementation is the specific treatment.
Other causes include Reye syndrome (post-viral, ASA-associated; rare since ASA pediatric guidance), organic acidurias (pediatric inborn errors), urease-producing UTI organisms (Proteus, Klebsiella), portosystemic shunts (TIPS, congenital), and primary mitochondrial disease.
3. Diagnostic Workup
Arterial ammonia level is the gold standard. Sample must be drawn free-flowing (no tourniquet), placed on ice, and processed within 30 minutes; venous samples have higher artifactual values. Severity thresholds: 50–100 µmol/L mild, 100–150 moderate, 150–200 severe, >200 critical with cerebral edema risk.
Concurrent workup includes liver function panel + INR, complete blood count, basic metabolic panel (rule out hypokalemia + alkalosis driving NH3), arterial blood gas, lactate, drug levels (valproate, antiepileptics), and infection workup (CBC, blood cultures, urinalysis, paracentesis if ascites). When UCD is suspected, plasma amino acids, urine orotic acid, plasma carnitine, and acylcarnitine profile narrow the differential. CT or MRI brain is appropriate for any altered mental status to rule out intracranial pathology and assess for cerebral edema.
Trend of ammonia level matters more than the absolute value. A patient with NH3 280 µmol/L trending down to 200 is faring better than a patient with 220 trending up to 300. Serial ammonia levels every 4 to 6 hours are essential during acute management until a clear trajectory is established.
4. Treatment Stepwise
Treatment proceeds in three parallel tracks: reverse precipitants, lower ammonia, prevent cerebral injury.
Reverse precipitants. Stop offending drugs (valproate, topiramate). Treat sepsis with appropriate antibiotics. Control GI bleeding and avoid additional protein load from blood. Correct hypokalemia (drives renal NH3 production) and alkalosis (drives NH3 to NH4+ which is freely diffusible). Address constipation. Consider TIPS dysfunction or shunt issue.
Lower ammonia — gut. Lactulose 30–45 mL PO/NG q1-2h titrated to 3 soft stools per day. For grade III-IV HE or comatose patients, add lactulose retention enema 300 mL in 700 mL water rectally q4-6h. Rifaximin 550 mg PO BID reduces gut ammonia production via gut bacteria suppression and adds to lactulose for both acute and prevention. Neomycin 1g q6h is an older alternative but ototoxicity limits use.
Lower ammonia — systemic. Nitrogen scavengers — sodium benzoate + sodium phenylacetate IV (Ammonul) loading + maintenance — are essential for UCD-related hyperammonemia and useful for severe drug-induced cases. Carglumic acid is specific for NAGS deficiency. L-carnitine 50 mg/kg IV q4-6h is helpful for valproate-induced hyperammonemia. Arginine supplementation supports urea cycle function in some UCDs.
CRRT. Continuous RRT (CVVH or CVVHDF) is the most effective way to clear severe hyperammonemia and is indicated for ammonia >200 µmol/L with rising trend despite Rx, rapidly progressive encephalopathy, established cerebral edema, or refractory neonatal/pediatric UCD. Intermittent hemodialysis is insufficient due to rebound. CRRT can clear ammonia at rates of 30–50 µmol/L/hour and is typically continued until ammonia stabilizes below 100 µmol/L.
5. Outcomes & Prevention
Outcomes correlate with peak ammonia level and time to ammonia normalization. Hepatic encephalopathy from cirrhosis with prompt lactulose initiation has 80 percent recovery without permanent neurologic deficit. Severe hyperammonemia (NH3 >300) carries higher mortality (~50 percent) and survivors often have persistent cognitive impairment. UCD-related hyperammonemia in adult presentations has variable outcomes depending on time to specific therapy.
Prevention focuses on chronic management for cirrhotic patients (lifelong lactulose + rifaximin), avoidance of valproate in patients with subclinical urea cycle dysfunction (suspect with elevated baseline ammonia or unexplained encephalopathy on valproate), early recognition + treatment of HE precipitants, and structured screening for adult-onset UCD in patients with recurrent unexplained hyperammonemia.
Pearl
Reflexively check ammonia in any encephalopathic patient on valproate, topiramate, or carbamazepine — drug-induced hyperammonemia is the most missed adult ICU cause. Even therapeutic levels can drive severe hyperammonemia.Pitfall
Intermittent hemodialysis for severe hyperammonemia produces rebound within hours of stopping. CRRT (CVVHDF) is required for sustained clearance. Plan CRRT when NH3 exceeds 200 with rising trend rather than waiting for established cerebral edema.6. Practice Insights
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)In ICU hyperammonemia — hepatology, general critical care, and the occasional rare urea cycle defect — the diagnostic workup is more often the limiting step than the treatment. By the time the first ammonia level returns, the patient has often deteriorated and cerebral edema is established.
What the Guideline Misses
Guidelines list lactulose + rifaximin as backbone but understate how hard it is to administer adequate lactulose in the comatose intubated patient — gastric aspiration, large volumes, ileus risk all interfere. A practical response is to give a lactulose retention enema simultaneously with the NG dose for any grade III-IV HE rather than waiting for NG response. The other gap is the threshold for CRRT — a reasonable trigger is to activate CRRT planning when ammonia exceeds 200 and trends upward despite Rx, rather than waiting for 300 or established cerebral edema.
Patterns That Recur
Valproate-induced hyperammonemia in patients with no liver disease is the most missed cause in adult ICUs — encephalopathy attributed to ‘sepsis’ or ‘metabolic’ for hours before someone checks the ammonia. Reflex checking ammonia in any encephalopathy of unclear etiology is worthwhile, especially with valproate or topiramate exposure. The other recurring pattern is post-bariatric or chronic-TPN patients who develop adult-onset urea cycle defect unmasking — rare but real and often catastrophic.
A Bedside Heuristic
When ammonia is elevated and the patient is encephalopathic, the first question is whether NH3 is rising or falling — not the absolute number. A patient at 280 trending down to 200 is doing better than a patient at 220 trending up to 300, even though the snapshot looks worse for the former. Serial ammonia q4-6h until a clear trend is established is the practical approach, and the trend drives the CRRT decision more than the threshold.
47-year-old man on chronic valproate for bipolar disorder, new encephalopathy
A man in his late 40s with bipolar I on valproate 1500 mg daily for 8 years presented with 24 hours of progressive confusion. Initially attributed to UTI; CT head normal; LP normal. By ICU day 1 he was obtunded and intubated. The covering intensivist ordered ammonia — 380 µmol/L. Valproate level was therapeutic 88 mcg/mL. Valproate was held; lactulose 30 mL NG q2h + rectal 300 mL q4h was started, with rifaximin and L-carnitine 50 mg/kg IV q4h added. Ammonia at 24h was 220, at 48h 95. He was extubated day 4, neurologic recovery complete by week 2. He resumed bipolar treatment with lithium instead of valproate.
→ Reflexively check ammonia in any unexplained encephalopathy on valproate, topiramate, or carbamazepine — drug-induced hyperammonemia is the most missed cause in adult ICUs.
Protocol Adjustments Worth Considering
- Order an ammonia level reflexively in any encephalopathic patient on valproate, topiramate, or carbamazepine even without obvious liver disease — drug-induced hyperammonemia is missed too often.
- Give simultaneous NG + rectal lactulose for any grade III-IV hepatic encephalopathy rather than waiting for NG response — gastric aspiration and ileus interfere too often with effective oral dosing.
- Activate CRRT planning when ammonia exceeds 200 and is trending upward despite lactulose + scavengers — waiting for 300 or established cerebral edema costs neurologic outcome.
7. Frequently Asked Questions
- Stress Ulcer Prophylaxis in the ICU: Risk Stratification and Drug Selection
- Post-ICU Syndrome (PICS): Cognitive, Physical, Mental Health Recovery
- Refeeding Syndrome: Identification, Prevention, and ICU Management Protocol
- Pediatric Anaphylaxis: Recognition, IM Epinephrine Dosing, and Discharge Planning
- Post-Cardiac Arrest Care: Targeted Temperature Management, Hemodynamics, and Neuroprognostication
- Heat Stroke and Hyperthermia: Emergency Management